公开(公告)号：US20230250079A1

公开(公告)日：2023-08-10

申请号：US18001464

申请日：2021-06-10

Applicant: LEO PHARMA A/S

Inventor： Mark ANDREWS ,  Morten Dahl SØRENSEN ,  Mogens LARSEN ,  Nicolas DEVAUX ,  Vinicius BARROS RIBEIRO DA SILVA ,  Quentin PERRON ,  Xifu LIANG ,  Jimmi Gerner SEIZBERG

IPC: C07D401/14 ,  C07D413/14 ,  C07D405/14 ,  C07D403/12

CPC classification number: C07D401/14 ,  C07D413/14 ,  C07D405/14 ,  C07D403/12

Abstract: The present disclosure relates to a compound according to formula I




and pharmaceutically acceptable salts, hydrates, or solvates thereof. The disclosure further relates to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases, e.g. dermal diseases, with said compounds, and to the use of said compounds in the manufacture of medicaments.

公开(公告)号：US20200323869A1

公开(公告)日：2020-10-15

申请号：US16468444

申请日：2017-12-12

Applicant: LEO PHARMA A/S

Inventor： Xifu LIANG ,  Jens LARSEN ,  Simon Feldbaek NIELSEN ,  Peter ANDERSEN

IPC: A61K31/55 ,  C07D491/20

Abstract: The present invention relates to novel substituted pyrazoloazepin-4-ones with phosphodiesterase inhibitory activity, as well as to their use as therapeutic agents in the treatment of inflammatory diseases and conditions.

公开(公告)号：US20220362259A1

公开(公告)日：2022-11-17

申请号：US17303955

申请日：2021-06-10

Applicant: LEO Pharma A/S

Inventor： Xifu LIANG ,  Jens LARSEN ,  Simon Feldbaek NIELSEN ,  Peter ANDERSEN

IPC: A61K31/55 ,  C07D491/20

Abstract: The present invention relates to novel substituted pyrazoloazepin-4-ones with phosphodiesterase inhibitory activity, as well as to their use as therapeutic agents in the treatment of inflammatory diseases and conditions.

公开(公告)号：US20220162191A1

公开(公告)日：2022-05-26

申请号：US17436885

申请日：2020-03-06

Applicant: LEO PHARMA A/S

Inventor： Xifu LIANG ,  Kevin Neil DACK ,  Peter ANDERSEN ,  Morten Dahl SØRENSEN ,  Mark ANDREWS ,  Alan Stuart JESSIMAN

IPC: C07D403/12 ,  C07D401/14 ,  C07D401/12 ,  C07D413/14 ,  C07D471/08 ,  C07D417/14 ,  C07D491/107 ,  C07D491/048 ,  C07D403/14 ,  C07D405/14

Abstract: The present invention relates to a compound according to formula I and pharmaceutically acceptable salts, hydrates, or solvates thereof. The invention further relates to, to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases, e.g. dermal diseases, with said compounds, and to the use of said compounds in the manufacture of medicaments.

公开(公告)号：US20200010477A1

公开(公告)日：2020-01-09

申请号：US16468420

申请日：2016-12-12

Applicant: LEO Pharma A/S

Inventor： Xifu LIANG ,  Jens LARSEN ,  Simon Feldbaek NIELSEN ,  Peter ANDERSEN

IPC: C07D491/20

Abstract: The present invention relates to novel substituted pyrazoloazepin-4-ones with phosphodiesterase inhibitory activity, as well as to their use as therapeutic agents in the treatment of inflammatory diseases and conditions.

公开(公告)号：US20190330223A1

公开(公告)日：2019-10-31

申请号：US16468429

申请日：2016-12-12

Applicant: LEO Pharma A/S

Inventor： Xifu LIANG ,  Jens LARSEN

IPC: C07D491/20

Abstract: The present invention relates to novel pyrazoloazepin-8-ones with phosphodiesterase inhibitory activity, as well as to their use as therapeutic agents in the treatment of inflammatory diseases and conditions.